– Study with another anti-Covid-19 candidate named Mambisa is approved in Cuba
Havana, Nov 21 (Prensa Latina) More than 80 percent of the population in Cuba (8,991,195) completed the anti-Covid-19 vaccination scheme, reported by the Ministry of Public Health (Minsap).
At the end of November 18, 10 million 118 thousand 526 people received at least one dose of Soberana 02 or Soberana Plus, from the Finlay Vaccine Institute, or Abdala, developed by the Center for Genetic Engineering and Biotechnology, and with a second injection nine million 155 thousand 120.
With three managed units, the figure rises to eight million 520 thousand 386 individuals.
Until the aforementioned date, 27 million 794 thousand 32 doses were administered, the Ministry of Health specified.
Cuba continues to lead in immunization in the region with 89 percent of its population protected against this disease, followed by Chile (87 percent), Uruguay (80) and Brazil (76), according to the digital site Our World in Data at the close November 19.
For its part, the Center for State Control of Medicines, Equipment and Medical Devices (Cecmed) approved the start of a clinical study of a booster dose with the anti-Covid-19 vaccine candidate Mambisa.
In its Twitter account, the Center for Genetic Engineering and Biotechnology (CIGB), developer of the drug, specified that it will be applied to previously vaccinated subjects to evaluate its effect and safety.
Mambisa, applied by nasal spray, drop dispenser or by means of a Cuban syringe device, is a unique formulation of this type based on the platform of recombinantly produced antigens, technology with high security, according to official information.
"An Island on a Continent" 